XBI

The State Street SPDR S&P Biotech ETF (XBI) is designed to closely track the total return performance of the S&P Biotechnology Select Industry Index, prior to accounting for fees and expenses. Its primary objective is to offer investors targeted exposure exclusively to the biotechnology segment of the market. A distinguishing characteristic is its underlying modified equal-weighted index, which fosters a diversified portfolio by ensuring balanced representation across large, mid, and small-capitalization biotech companies, thereby minimizing concentration risk. This structure makes XBI a precise tool for investors seeking to implement strategic or tactical allocations within the biotech sector, providing a more focused investment approach compared to traditional, broader sector funds.